Publications (original articles or review articles) published in 2024 from OUS - Department of Clinical Cancer Research
18 publications found
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720
Long-term cardiac effects of modern treatment for Hodgkin's lymphoma
Cardiooncology, 10 (1), 19
DOI 10.1186/s40959-024-00222-4, PubMed 38576044
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
NPJ Breast Cancer, 10 (1), 30
DOI 10.1038/s41523-024-00638-2, PubMed 38653982
Distressed personality is associated with late adverse effects in long-term survivors of Hodgkin lymphoma
Acta Oncol, 63, 600-606
DOI 10.2340/1651-226X.2024.40312, PubMed 39099321
Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms
Br J Cancer, 131 (4), 676-684
DOI 10.1038/s41416-024-02773-w, PubMed 38909137
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Clin Cancer Res, 30 (20), 4572-4583
DOI 10.1158/1078-0432.CCR-24-0012, PubMed 38771739
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Clin Colorectal Cancer (in press)
DOI 10.1016/j.clcc.2024.11.004, PubMed 39743478
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers
Int J Mol Sci, 25 (1)
DOI 10.3390/ijms25010586, PubMed 38203757
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Lancet Gastroenterol Hepatol, 9 (3), 205-217
DOI 10.1016/S2468-1253(23)00405-3, PubMed 38237621
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
Oncoimmunology, 14 (1), 2440967
DOI 10.1080/2162402X.2024.2440967, PubMed 39703053
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Ann Oncol, 35 (12), 1191-1199
DOI 10.1016/j.annonc.2024.08.2330, PubMed 39306585
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med, 391 (18), 1709-1720
DOI 10.1056/NEJMoa2404139, PubMed 38899716
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
Mol Ther, 32 (6), 2021-2029
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 36 (11), e13428
DOI 10.1111/jne.13428, PubMed 38937137
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13760, PubMed 39545921
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
Immunooncol Technol, 24, 101009
DOI 10.1016/j.iotech.2024.101009, PubMed 39697983